No photo of Gian Carlo Antonini Cappellini

View Scopus Profile

Gian Carlo Antonini Cappellini

  • 1548 Citations
  • 12 h-Index
20002019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Gian Carlo Antonini Cappellini is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Neutrophils Medicine & Life Sciences
Lymphocytes Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Eosinophils Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2000 2019

  • 1548 Citations
  • 12 h-Index
  • 38 Article
  • 2 Comment/debate
  • 1 Letter
4 Citations (Scopus)

MiR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

Caporali, S., Amaro, A., Levati, L., Alvino, E., Lacal, P. M., Mastroeni, S., Ruffini, F., Bonmassar, L., Antonini Cappellini, G. C., Felli, N., Carè, A., Pfeffer, U. & D'Atri, S., Jun 21 2019, In : Journal of Experimental and Clinical Cancer Research. 38, 1, 272.

Research output: Contribution to journal › Article

Open Access
Vascular Endothelial Growth Factor A
Melanoma
Down-Regulation
MicroRNAs
Immunoblotting
1 Citation (Scopus)

Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386

on behalf of the Italian Melanoma Intergroup (IMI), Mar 2 2018, In : Frontiers in Immunology. 9, MAR, 403.

Research output: Contribution to journal › Comment/debate

Conflict of Interest
Melanoma
Survival
Italy
Genes

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Queirolo, P., Dozin, B., Morabito, A., Banelli, B., Carosio, R., Fontana, V., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Ascierto, P. A., Madonna, G., Simeone, E., De Galitiis, F., Antonini Cappellini, G. C., Marchetti, P., Guida, M., Tommasi, S., Ghilardi, L., Merelli, B., Fava, P. & 7 others, Osella-Abate, S., Guidoboni, M., Romani, M., Ferone, D., Spagnolo, F., Pistillo, M. P. & (IMI), I. M. I., 2018, In : European journal of cancer. 97, p. 59-61 3 p.

Research output: Contribution to journal › Article

3 Citations (Scopus)

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI), Jul 1 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journal › Letter

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI), Jul 2018, In : European Journal of Cancer. 97, p. 59-61 3 p.

Research output: Contribution to journal › Article